{"id":587117,"date":"2025-12-22T00:00:00","date_gmt":"2025-12-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2025-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2025\/"},"modified":"2026-08-15T23:21:57","modified_gmt":"2026-08-15T23:21:57","slug":"algoim0057-2025-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2025","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2025-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2025\/","title":{"rendered":"Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2025"},"content":{"rendered":"<p>Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three subtypes: constipation-predominant, diarrhea-predominant, and mixed. This analysis focuses on the diarrhea-predominant subtype (IBS-D). Available treatments are limited; few drugs have FDA approval for IBS-D, and most drugs are used off-label. The primary focus remains on alleviating diarrhea symptoms while providing psychological support to patients. Various approaches include the use of antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals\u2019 Lotronex), an antibiotic (Salix Pharmaceuticals\u2019 Xifaxan), and an opioid delta receptor antagonist (AbbVie\u2019s Viberzi).<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?<\/li>\n<li>How have Viberzi and Lotronex been integrated into the treatment algorithm, and what is their source of business?<\/li>\n<li>What percentage of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of IBS-D patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul>\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies:<\/strong> AbbVie, Salix, Sebela Pharmaceuticals<\/p>\n<p><strong>Key drugs:<\/strong> Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulfate \/ scopolamine, SSRIs, SNRIs, tricyclic antidepressants.<\/p>\n<p><strong>Key feature: <\/strong>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-587117","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-irritable-bowel-syndrome","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/587117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=587117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}